Why Restart Eliquis for DVT Prevention
Eliquis (apixaban) should be restarted after procedures or interruptions because discontinuing anticoagulation leaves patients vulnerable to recurrent venous thromboembolism (VTE), which carries significant morbidity and mortality risk, while apixaban provides highly effective prevention with a favorable bleeding profile.
The Core Rationale for Restarting Anticoagulation
The fundamental reason to restart Eliquis centers on preventing recurrent VTE, which is the primary driver of morbidity and mortality in these patients. Here's the algorithmic approach:
Risk of Recurrence Without Anticoagulation
Indefinite treatment reduces recurrent VTE risk by approximately 90%, but anticoagulants don't eliminate future risk after discontinuation 1. The recurrence rates vary by clinical scenario:
- Unprovoked VTE: 4.5% per year after stopping treatment 1
- Provoked VTE (transient risk factors): 2.5% per year 1
- Cancer-associated VTE: ~20% in first 12 months 1
- First year after withdrawal: Up to 10% recurrence rate 1
When Recurrent VTE Occurs
In patients with prior PE, recurrence manifests as symptomatic PE more frequently than DVT, making the stakes particularly high 1. This means stopping anticoagulation in PE patients carries life-threatening risk.
Specific Scenarios for Restarting Eliquis
After Surgical/Procedural Interruption
Restart Eliquis as soon as adequate hemostasis is established 2:
- Low bleeding risk procedures: Restart 24-48 hours post-procedure (typically 48 hours) 3
- Moderate/high bleeding risk procedures: Restart 48-72 hours post-procedure (typically 72 hours) 3
- Bridging is NOT required during the 24-48 hour interruption period 2
The French perioperative guidelines 4 specify that when surgical hemostasis is obtained, DOACs can be restarted at full therapeutic doses without the need for initial prophylactic dosing.
Extended/Long-term Prevention
For patients who have completed initial treatment (typically 6 months), the decision algorithm is:
1. Unprovoked VTE + Low-Moderate Bleeding Risk:
- Continue Eliquis indefinitely at reduced dose (2.5 mg twice daily) 5, 6
- This provides 90% reduction in recurrent VTE 1
- Reduced-dose apixaban (2.5 mg BID) after 6 months is as effective as full-dose with lower bleeding risk 5, 7
2. Provoked VTE (transient risk factor) + Enduring Risk Factors:
- Restart/continue Eliquis 2.5 mg twice daily for extended therapy 8
- Recent 2025 HI-PRO trial showed 1.3% recurrence with apixaban vs 10.0% with placebo (HR 0.13,95% CI 0.04-0.36) 8
- Major bleeding remained minimal (1 patient vs 0 in placebo) 8
3. Cancer-Associated VTE:
- Continue anticoagulation indefinitely while cancer remains active 1, 6
- For extended therapy beyond 6 months: Reduced-dose apixaban 2.5 mg BID is superior 7
- API-CAT trial (2025) showed reduced-dose was noninferior for VTE prevention (2.1% vs 2.8%) but with significantly less bleeding (12.1% vs 15.6%, HR 0.75) 7
Apixaban's Specific Advantages
Apixaban offers unique benefits that justify its restart over alternatives:
Efficacy Profile
- Noninferior to enoxaparin/warfarin for acute VTE treatment (AMPLIFY trial: 2.3% vs 2.7% recurrence) 9, 10
- Significantly reduces recurrent VTE vs placebo in extended treatment (AMPLIFY-EXT) 1, 10
- Reduces hospitalizations by 20% compared to warfarin (HR 0.804, P=0.045) 11
Safety Profile
- Major bleeding 0.6% vs 1.8% with warfarin (RR 0.31, P<0.001) 9, 10
- Lower bleeding than warfarin in extended therapy without increased VTE risk 12
- Reduced-dose option (2.5 mg BID) after 6 months maintains efficacy with minimal bleeding 5, 7
Practical Advantages
- No parenteral lead-in required (unlike edoxaban or dabigatran) 13
- No routine monitoring needed 14, 15
- Twice-daily dosing may improve compliance through routine 13
- Predictable pharmacokinetics allow fixed dosing 14
Critical Pitfalls to Avoid
1. Don't delay restart excessively:
- Balance hemostasis concerns against rapidly rising VTE risk
- Use the 48-72 hour window as maximum for most procedures 3
2. Don't use prophylactic dosing initially:
- Restart at full therapeutic dose unless specifically indicated otherwise 4
- Exception: Post-orthopedic surgery prophylaxis uses 2.5 mg BID 2
3. Don't forget dose reduction for extended therapy:
- After 6 months of full-dose treatment, reduce to 2.5 mg BID for indefinite prevention 5, 2, 7
- This maintains efficacy while reducing bleeding risk
4. Caution in specific populations:
- GI/genitourinary malignancies: Higher mucosal bleeding risk with DOACs; consider LMWH 16, 13
- Severe renal impairment (CrCl <15 mL/min): Insufficient safety data 9, 13
- Mechanical heart valves: Absolute contraindication for all DOACs 17
The Bottom Line
Restart Eliquis because the alternative—recurrent VTE—carries 4.5-10% annual risk with potentially fatal consequences, while apixaban provides 90% risk reduction with major bleeding rates under 1% in most populations. The 2025 evidence strongly supports reduced-dose continuation (2.5 mg BID) for extended therapy, offering optimal balance of efficacy and safety 8, 7.